Mechanisms of Resistance to Intermittent Androgen Deprivation in Patients with Prostate Cancer Identified by a Novel Computational Method

Jason D. Morken\textsuperscript{1,2}, Aaron Packer\textsuperscript{1}, Rebecca A. Everett\textsuperscript{1}, John D. Nagy\textsuperscript{1,3}, and Yang Kuang\textsuperscript{1}

Abstract

For progressive prostate cancer, intermittent androgen deprivation (IAD) is one of the most common and effective treatments. Although this treatment is usually initially effective at regressing tumors, most patients eventually develop castration-resistant prostate cancer (CRPC), for which there is no effective treatment and is generally fatal. Although several biologic mechanisms leading to CRPC development and their relative frequencies have been identified, it is difficult to determine which mechanisms of resistance are developing in a given patient. Personalized therapy that identifies and targets specific mechanisms of resistance developing in individual patients is likely one of the most promising methods of future cancer therapy. Prostate-specific antigen (PSA) is a biomarker for monitoring tumor progression. We incorporated a cell death rate (CDR) function into a previous dynamical PSA model that was highly accurate at fitting clinical PSA data for 7 patients. The mechanism of action of IAD is largely induction of apoptosis, and each mechanism of resistance varies in its CDR dynamics. Thus, we analyze the CDR levels and their time-dependent oscillations to identify mechanisms of resistance to IAD developing in individual patients. Cancer Res; 74(14): 3673–83. ©2014 AACR.

Major Findings

Here, we introduce a novel computational method called cell death rate (CDR) analysis that uses a mathematical model validated by clinical data to identify the major mechanism of treatment resistance developing in a given patient. Although CDR analysis may be applicable to other cancers, we use it here to predictively diagnose the major mechanism of castration resistance developing in individual patients with prostate cancer after a period of IAD. Our results are consistent with biologic literature, and this mathematical method using CDR analysis may significantly improve personalized treatment of CRPC and other cancers.

Introduction

Prostate cancer and treatment

In this work, we limit our attention to prostatic adenocarcinomas of non-neuroendocrine origin as this entity has by far the greatest clinical significance of all prostate tumors. Healthy prostatic epithelial cells and most malignant prostatic epithelial cells exhibit some degree of dependence on androgens, including testosterone and dihydrotestosterone (DHT), for proliferation and survival (1–5). The contribution androgens provide to cell proliferation and survival is mediated by the androgen receptor (AR) axis. It is well known that AR signaling regulates expression of genes involved in proliferation and survival and is generally accepted to be the primary driver of tumor progression in adenocarcinomas (1, 2, 4–7). AR signaling inhibition, therefore, regresses tumors (2, 4, 8, 9).

The most common and effective treatment for progressive prostate cancer is androgen-deprivation therapy (5, 6). The mechanism of action of this therapy is largely induction of apoptosis, contingent on prostate cancer cells being dependent on androgens, via the AR axis, for survival (2–5). Androgen deprivation can be accomplished by surgical castration (orchectomy) or chemical castration (with drugs). The latter method is commonly carried out by "total androgen blockade," which combines lateinizing hormone-releasing hormone (LHRH) analogues and antiandrogens (10). Chemical castration is almost universally effective at regressing tumors initially; however, almost all patients eventually develop resistance to treatment and advance to a more aggressive stage, for which there is no effective treatment (5, 6, 10, 11). This
Quick Guide to Equations and Assumptions

This study builds off of the previous work by Jackson, Ieda and colleagues, and especially Portz and colleagues. As these authors did, we model two populations of prostate cancer cells within a single patient. One population has a castration-sensitive (CS) phenotype and the other is castration resistant (CR). For simplicity, we will refer to these different populations as "strains." The sizes of each strain at time $t$ are represented by $X_i(t)$ and $X_2(t)$. Dynamics of these populations are modeled by the following system of ordinary differential equations:

$$\frac{dX_i}{dt} = \mu_m \left(1 - \frac{Q_i}{K_i}\right) - \left(D_i(Q_i)X_i - \lambda_1(Q_i)X_i - \lambda_2(Q_i)X_i\right),$$

$$\frac{dX_2}{dt} = \mu_m \left(1 - \frac{Q_2}{K_2}\right) - \left(D_2(Q_2)X_2 - \lambda_1(Q_2)X_2 - \lambda_2(Q_2)X_2\right),$$

where $X_i(t)$ represents the size of the $i$th strain at time $t$. (See Table 1 for a comprehensive list of parameter interpretations and values.) Cell population dynamics are driven by intracellular concentration, or cell quota, of bound androgen receptors (AR), which we denote $Q_i(t)$. Here, $i \in \{1, 2\}$ refers to the strain identity. Androgen is viewed as an ecological resource on which both proliferation and cell mortality depend. As did Portz and colleagues, we represent androgen-dependent proliferation using an established formalism from mathematical ecology called the Droop model. In this context, the Droop form for per capita proliferation rate of strain $i$ becomes $\mu_m \left(1 - \frac{Q_i}{K_i}\right)$, where positive constants $\mu_m$ and $q_i$ represent maximum proliferation rate and minimum cell quota required for proliferation, respectively. Because strains 1 and 2 are CS and CR, respectively, and because CR cells are less dependent on androgens and can proliferate at aberrantly low levels of serum androgen, we assume that $q_2 < q_1$.

Portz and colleagues assume a constant per capita mortality rate for both strains. However, androgen-deprivation therapy works not only by inhibiting growth and proliferation, but also by inducing apoptosis in prostate cancer cells. To capture this reality, we represent per capita mortality in the $i$th strain as the following CDR function:

$$\frac{D_i(Q_i)}{CDR} = \frac{d_i R^2}{Q_i^2 + R^2} + \frac{\delta_i}{At Death}.$$  \hspace{1cm} (C)

The first term on the right-hand side expresses androgen-dependent apoptosis, where positive constants $R_i$ and $\alpha$ are shape parameters playing similar roles to the half-saturation constant and Hill coefficients in Hill functions; together they describe how sensitively apoptosis responds to changes in cell quota. Positive constants $d_i$ are the maximal apoptosis rates induced by complete absence of bound ARs. Finally, positive constants $\delta_i$ represent androgen-independent cell mortality.

The switching rates between cell phenotypes are represented by:

$$\lambda_1(Q_i) = c_1 \frac{K_1^2}{Q_i^2 + K_1^2},$$

$$\lambda_2(Q_2) = c_2 \frac{Q_2^2}{Q_2^2 + K_2^2}.$$  \hspace{1cm} (D)

(E)

Shape parameters $K_1, K_2,$ and $n$ determine the sensitivity of the switch rates to variations in cell quota, and parameters $c_1$ and $c_2$ are maximal switch rates when cell quota approaches 0 or infinity, respectively. All are positive constants.

The cell quota, $Q_i(t)$, is modeled by:

$$\frac{dQ_i}{dt} = \frac{q_m - Q_i}{q_m - q_i} \frac{A}{A + \nu_b} - \frac{\mu_m(Q_i - q_i)}{Growth~dilution} - \frac{bQ_i}{Degradation}.$$  \hspace{1cm} (F)

Here, we interpret the meaning of $Q_i(t)$ slightly differently than did Portz and colleagues. Because $Q_i(t)$ is the (average) bound AR concentration in the $i$th strain and ARs are intracellular, we view the first term in the cell quota equation as including two processes: androgen--AR binding inside the cell and cellular regulation of AR concentration. With this interpretation, $A(t)$ is the...
PSA is secreted by these cells into the blood serum and inhibits intraprostatic androgen synthesis) and enzalutamide (a second-generation AR antagonist), has further con- 

because these cells are still dependent on androgens for survival (5). The recent clinical ef- 

Because continuous androgen deprivation (CAD) provides a 

The recent clinical ef- 

Because PSA is only produced in epithelial cells, our model only considers epithelial cells and, thus, we only model carcinomas. The 

Because IAD induces cell death only during on-treatment periods, CDRs oscillate in populations that depend on androgens for 

Several mathematical models have been developed with the goal of fitting model output to clinical PSA data throughout the 

Several mathematical models have been developed with the goal of fitting model output to clinical PSA data throughout the 

Identifying CRPC Mechanisms in Individual Patients

advanced stage has traditionally been referred to as androgen- 

identifying primary tumor cells. AR signaling is considered the primary driver of 

increasing PSA levels are characteristic of tumor progression, whereas decreasing PSA levels are characteristic of tumor regression. For IAD, patients are usually put on treatment until their PSA levels fall below some threshold value, usually <4 ng/mL, and taken off-treatment until PSA rises above some threshold level, usually >10 ng/mL (10).

Several mathematical models have been developed with the goal of fitting model output to clinical PSA data throughout the course of IAD (19–23). Here, we address how a mechanistic model of prostate cancer that takes an individual patient’s serum androgen levels as input, and uses data fitting to clinical PSA data to estimate parameters, might be used to inform clinicians of the inherent mechanism(s) of treatment resistance in individual patients.

Major mechanisms of treatment resistance

Although most prostate cancer cells exhibit some degree of dependence on androgens for survival, as tumors continue to advance to a more progressive state, the degree of dependence tends to decrease. Several pathways to CRPC development have been identified with varying degrees of androgen dependence (see ref. 1 for detailed review of these mechanisms).
Later, we attempt to quantify this variation in dependence and use it to identify which mechanism is developing in individual patients. Clinical identification of these mechanisms in individual tumors still suffers from a lack of maturity because CRPC tissue is difficult to obtain and study (11). Hence, mathematical models may be a potentially powerful clinical tool for analyzing mechanisms of CRPC development. Here, we highlight mechanisms that lead to CRPC, which we propose as a tool for analyzing mechanisms of CRPC development. Here, we use it to identify which mechanism is developing in individual patients. Clinical identification of these mechanisms in individual tumors still suffers from a lack of maturity because CRPC tissue is difficult to obtain and study (11). Hence, mathematical models may be a potentially powerful clinical tool for analyzing mechanisms of CRPC development. Here, we highlight mechanisms that lead to CRPC, which we propose as a tool for analyzing mechanisms of CRPC development.

### Table 1. Static parameter values, free parameter ranges, and parameter interpretations

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
<th>Value</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \mu_0 )</td>
<td>Maximum proliferation rate</td>
<td>0.020–0.040 day(^{-1} )</td>
<td>40</td>
</tr>
<tr>
<td>( q_1 )</td>
<td>Minimum CS cell quota</td>
<td>0.180–0.320 nmol/L</td>
<td>19</td>
</tr>
<tr>
<td>( q_2 )</td>
<td>Minimum CR cell quota</td>
<td>0.100–0.210 nmol/L</td>
<td>19</td>
</tr>
<tr>
<td>( \sigma_1 )</td>
<td>CS PSA production rate</td>
<td>0.000–0.290 ag/mL/cell/d</td>
<td></td>
</tr>
<tr>
<td>( \sigma_2 )</td>
<td>CR PSA production rate</td>
<td>0.015–0.350 ag/mL/cell/d</td>
<td></td>
</tr>
<tr>
<td>( \sigma_0 )</td>
<td>Baseline PSA production rate</td>
<td>0.003–0.035 ag/mL/cell/d</td>
<td></td>
</tr>
<tr>
<td>( d_1 )</td>
<td>Maximum CS androgen-dependent apoptosis rate</td>
<td>0.002–0.030 day(^{-1} )</td>
<td></td>
</tr>
<tr>
<td>( d_2 )</td>
<td>Maximum CR androgen-dependent apoptosis rate</td>
<td>0.000–0.006 day(^{-1} )</td>
<td></td>
</tr>
<tr>
<td>( R_1 )</td>
<td>CS androgen-dependent apoptosis half-saturation level</td>
<td>0.500–2.040 nmol/L</td>
<td></td>
</tr>
<tr>
<td>( R_2 )</td>
<td>CR androgen-dependent apoptosis half-saturation level</td>
<td>1.130–3.500 nmol/L</td>
<td></td>
</tr>
<tr>
<td>( \delta_1 )</td>
<td>CS androgen-independent mortality rate</td>
<td>0.000–0.013 day(^{-1} )</td>
<td></td>
</tr>
<tr>
<td>( \delta_2 )</td>
<td>CR androgen-independent mortality rate</td>
<td>0.010–0.016 day(^{-1} )</td>
<td></td>
</tr>
<tr>
<td>( \alpha )</td>
<td>Androgen-dependent apoptosis rate shape parameter</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>( c_1 )</td>
<td>Maximum CS to CR switching rate</td>
<td>0.00015 day(^{-1} )</td>
<td>19, 23</td>
</tr>
<tr>
<td>( c_2 )</td>
<td>Maximum CR to CS switching rate</td>
<td>0.0001 day(^{-1} )</td>
<td>19</td>
</tr>
<tr>
<td>( K_1 )</td>
<td>CS to CR switching half-saturation level</td>
<td>0.8 nmol/L</td>
<td>19</td>
</tr>
<tr>
<td>( K_2 )</td>
<td>CR to CS switching half-saturation level</td>
<td>1.7 nmol/L</td>
<td>19</td>
</tr>
<tr>
<td>( n )</td>
<td>Switching rate shape parameter</td>
<td>3</td>
<td>19</td>
</tr>
<tr>
<td>( q_m )</td>
<td>Maximum cell quota</td>
<td>5 nmol/L</td>
<td></td>
</tr>
<tr>
<td>( v_m )</td>
<td>Maximum uptake rate</td>
<td>0.27 [nmol/L]/d</td>
<td></td>
</tr>
<tr>
<td>( v_0 )</td>
<td>Uptake rate half-saturation level</td>
<td>4 nmol/L</td>
<td>19</td>
</tr>
<tr>
<td>( b )</td>
<td>Intracellular androgen degradation rate</td>
<td>0.09 day(^{-1} )</td>
<td>19, 23</td>
</tr>
<tr>
<td>( \rho_1 )</td>
<td>CS PSA production half-saturation level</td>
<td>1.3 nmol/L</td>
<td></td>
</tr>
<tr>
<td>( \rho_2 )</td>
<td>CR PSA production half-saturation level</td>
<td>1.1 nmol/L</td>
<td></td>
</tr>
<tr>
<td>( m )</td>
<td>PSA production function exponent</td>
<td>3</td>
<td>19</td>
</tr>
<tr>
<td>( \varepsilon )</td>
<td>PSA clearance rate</td>
<td>0.08 day(^{-1} )</td>
<td>19, 23</td>
</tr>
</tbody>
</table>

**NOTE:** *Mutation* parameters in Portz and colleagues (19) are called "switching" parameters here to reflect the new interpretation of adaptation and accommodation. \( X_i \) are in units of \( 10^9 \) cells.

*These parameter ranges were set such that min\( \{D_i(Q_i)\} \geq 0.0076 \) and max\( \{D_i(Q_i)\} \leq 0.06 \) (see ref. 40).

Suggested that increased AR stability may be a mechanism leading to CRPC (1). Increased local androgen production can result from constitutive activation of 5α-reductase, which converts testosterone to DHT in prostate cells. For example, the V89L mutation in the gene coding for 5α-reductase leads to an increase in its activity (1). Furthermore, some CRPC cells may be able to synthesize the androgens themselves from cholesterol or other androgenic precursors (1, 5, 6).

### The hypersensitivity pathway.

Cells using this as their major mechanism have a lower androgen threshold for proliferation and survival but remain completely dependent on androgens. We consider three specific pathways to hypersensitivity: amplification and overexpression of AR, increased AR stability, and increased local androgen production. Overexpression of AR is characteristic of most CRPC cases (7, 15, 24). It has been demonstrated that overexpression of wild-type AR is adequate to fully transform a CS tumor into a CR tumor (24). AR amplification is one of the most common genetic aberrations to occur in CRPC (15). It has been suggested that 80% of CRPC cases exhibit elevated AR gene copy number whereas 30% exhibit high-level amplification (15). It has also been suggested that increased AR stability may be a mechanism leading to CRPC (1). Increased local androgen production can result from constitutive activation of 5α-reductase, which converts testosterone to DHT in prostate cells. For example, the V89L mutation in the gene coding for 5α-reductase leads to an increase in its activity (1). Furthermore, some CRPC cells may be able to synthesize the androgens themselves from cholesterol or other androgenic precursors (1, 5, 6).

**The promiscuous receptor pathway.** Promiscuous ARs generally arise from missense mutations in the ligand-binding domain that decrease the specificity of the AR for a particular ligand. These mutations broaden the group of ligands that activate the AR, such that the AR obtains the ability to bind to and be activated by other nonandrogen agonists in addition to androgens (1, 4). Potential nonandrogen agonists include estrogen, progesterone, cortisol, antiandrogens, or adrenal androgens such as DHEA (4). For example, the most common promiscuous AR mutation is T877A, which is endogenously expressed in androgen-sensitive LNCaP cell lines in which it was first discovered (4, 12). Taplin and colleagues found the T877A mutation to be present in 30% of prostate cancer bone metastases (25). The T877A-mutant AR still binds to, and is,
thus, activated by, testosterone and DHT. However, alanine replaces the threonine residue at position 877 and allows ligands other than testosterone and DHT to also fit in the binding pocket and activate the receptor (12). Promiscuous ARs with complete loss of responsiveness to androgens are extremely rare (4). Although mutations have been identified that reduce affinity for DHT relative to the wild-type AR, nearly all identified promiscuous ARs are still activated by DHT (4). We, therefore, assume that all CR cells with promiscuous ARs retain responsiveness to androgens; however, they are less dependent on these androgens than cells with hypersensitivity.

The outlaw receptor pathway. Outlaw receptors are steroid hormone receptors that are activated by ligand-independent mechanisms. No mutations in the AR gene coding region have been identified such that the AR is activated by ligand-independent mechanisms (1). Rather, this pathway apparently involves the wild-type receptor or AR splice variants, because the AR gene sequence is not changed, and may still exhibit responsiveness to androgens. There have been several AR splice variants identified such that the ligand-binding domain is absent and these ARs remain ligand independently constitutively active (6, 26). However, exclusive expression of AR splice variants is very rare. The vast majority of cells expressing AR splice variants also express wild-type AR (7). Therefore, most tumors developing resistance through outlaw AR splice variant expression should still exhibit responsiveness to androgens while maintaining active AR signaling in the absence of androgens. It has been shown the wild-type AR can be activated by growth factors, receptor tyrosine kinases, MAPK, AKT, and other activators in a ligand-independent fashion (1). If no ligands are available other than androgens in a cell with promiscuous ARs, the cell then depends on androgens. No ligands are available in a cell with outlaw AR, AR signaling remains active. Thus, this pathway is less dependent on androgens than the promiscuous receptor pathway because it is completely ligand independent.

The bypass pathway. This mechanism results from constitutive activation of pathways that directly inhibit apoptosis in the absence of androgens (1). One mechanism may be the upregulation of BCL2, BCLX, or MCL1, genes known to directly inhibit apoptosis (1, 4, 10). Prostatic secretory epithelial cells normally do not produce BCL2, but many CRPC cells do (1, 10). However, besides prostatic sarcomas and neuroendocrine carcinomas, which our model does not consider, the complete bypass of AR signaling does not provide a selective advantage (4, 6). This pathway is the least dependent on androgens for survival.

Materials and Methods

Formulation of the mathematical model

We extend the prostate cancer IAD treatment model by Portz and colleagues (19) who consider tumors as two cell populations: cells that are castration sensitive (CS) and those that are castration resistant (CR). The mathematical model portrayed in the Quick Guide describes two populations of luminal secretory epithelial cells that secrete PSA (1). The CR population accounts for prostate cancer cells that have acquired at least one mechanism of treatment resistance. The static parameter values, free parameter value ranges, and their interpretations are listed in Table 1. Detailed model formulation and explanations can be found in (19) and are summarized in the Quick Guide above. What follows is a narrative summary of the equations and assumptions.

Here, we follow Portz and colleagues in assuming that proliferation of prostate carcinoma cells is more-or-less androgen dependent, this dependence can vary among cells in a given tumor, and cells can switch reversibly between CS and CR states. Our major extension of the Portz and colleagues’ model is the addition of an androgen-dependent cell-death rate (CDR) function, \( D_I(Q_i) \) (Equation C). We retain the Droop formalism (27), adapted from chemostat and ecologic models, to govern androgen-dependent proliferation, as well as the forms used by Portz and colleagues for androgen-dependent switching between CS and CR states—i.e., \( \lambda_1 \) and \( \lambda_2 \) (Equations A, B, D, and E).

In this model, androgen enters cells in which it can bind to and dissociate from ARs in the intracellular compartment. Androgen may also be metabolized or transported out of the system. The dynamics of these processes are governed by the cell quota (Equation F). Bound ARs alter cell proliferation, death and state-switching rates. In general, proliferation rates increase and mortality rates decrease with increasing concentration of bound ARs. The total AR concentration, both bound and unbound, is regulated in the cell quota equation such that the proliferation terms in Equations A and B can never become negative. In low androgen environments, state switching by prostate cells is biased in favor of the CR state. This bias is reversed in high androgen environments. Both cell strains secrete PSA to the serum at the same basic rate. However, strains may vary in how their PSA secretion rate depends on bound AR (see equation G).

It is an open question whether castration resistance evolves from selection acting on a small population of CR cells that exist in the tumor before treatment (the selection hypothesis), or whether CR strains arise during treatment (the adaptation hypothesis), or both (28, 29, 30). The role accommodative changes play is also not well understood. Here, by accommodating or whether CR strains may vary in how their PSA secretion rate depends on bound AR (see equation G).

It is an open question whether castration resistance evolves from selection acting on a small population of CR cells that exist in the tumor before treatment (the selection hypothesis), or whether CR strains arise during treatment (the adaptation hypothesis), or both (28, 29, 30). The role accommodative changes play is also not well understood. Here, by accommodating cell strains may vary in how their PSA secretion rate depends on bound AR (see equation G).

In the tumor before treatment (the selection hypothesis), or whether CR strains arise during treatment (the adaptation hypothesis), or both (28, 29, 30). The role accommodative changes play is also not well understood. Here, by accommodating cell strains may vary in how their PSA secretion rate depends on bound AR (see equation G).
from which it was derived. However, we interpret the switch as incorporating both adaptation and accommodation to cover all possible switching mechanisms. The adaptation label is supported by the fact that AR point mutations are rarely found in primary prostate cancer but are found in approximately 20% of CRPCs (11). Furthermore, one study showed that only two of 205 untreated prostate cancer cases had detectable AR amplification (31), and another study showed that 38% to 63% of metastatic CRPC cases exhibited high-level AR amplification (32, 33). This evidence strongly suggests that an oscillating androgen environment creates selective pressure inducing an adaptive switch. Although this evidence only shows evolution toward CRPC, it is possible that CR tumors could evolve back to CS if selective pressures change (e.g., androgen is reintroduced); although this return to castration sensitivity would be unlikely to be due to direct back mutation, we recognize that the phenotype can be regenerated by novel alterations of coding or control sequences to a variety of genes in a given resistance pathway. It is necessary to include accommodation into the interpretation because epigenetic modifications, which can lead to phenotypic switching, take place at a much higher rate than genetic modifications (34) and several epigenetic aberrations play a role in prostate cancer that can facilitate the phenotypic switch represented by $\lambda_1$ and $\lambda_2$ (35).

### CDR analysis

The CDR analysis method we propose here consists of analyzing the CDR levels and oscillations in response to intermittent treatment to determine which molecular basis is conferring treatment resistance in a given patient. The rationale behind CDR analysis is as follows:

1. The mechanism of action of IAD is largely induction of apoptosis, because all CS cells and most CR cells exhibit some degree of dependence on androgens for survival.
2. Because the treatment is intermittent, CDRs increase during on-treatment and decrease during off-treatment giving rise to CDR oscillations.
3. The amplitude of CDR oscillation in a given population reflects the degree to which that population depends on androgens for survival.
4. Each mechanism of treatment resistance varies in its dependence on androgens for survival.
5. In addition, CDR levels tell us whether or not there is a constitutively active antiapoptotic pathway inherent in the population (i.e., the bypass pathway). An exceedingly low CDR indicates there is.
6. We identify which major mechanism of treatment resistance is developing by analyzing the CDR levels and oscillations.

### Data

The data from Akakura and colleagues were obtained from seven patients with progressive prostate cancer undergoing IAD by total androgen blockade (9). Serum PSA and testosterone were assayed monthly to monitor therapy. Treatment was initiated and subsequently interrupted after serum PSA had been suppressed to adequately low levels for roughly six months. When PSA recovered past 15 to 20 ng/mL, treatment was reintiated for a new cycle.

Treatment induced rapid decreases in serum testosterone, with levels reaching approximately 0.5 to 1.0 nmol/L after about one or two months. These low levels were sustained until interruption of treatment, after which testosterone recovered relatively quickly, with some variation depending on the patient. The coupling of these changes to those of PSA varied across not only patients but also cycles of individual patients. Akakura and his colleagues suggested that these dynamics were due both to changes in androgen sensitivity and to the "dual effect" of androgen on PSA; namely, the cellular level (PSA synthesis and secretion) and the population level (proliferation and apoptosis; ref. 9). The model captures these effects via the dependence of $Q(t)$ (Equation F) on the serum androgen concentration $A(t)$. CDR analysis quantifies this behavior across cycles and patients in a way that is both simple and biologically meaningful.

For each patient, CDR values were calculated by fitting the model to the PSA data. To implement the serum androgen function, $A(t)$, testosterone data were interpolated using the same approach found in Portz and colleagues (19). The Nelder–Mead simplex algorithm (36) was then used to minimize the mean-square error (MSE) of the PSA data with the model solution $P(t)$ by varying the parameters $\mu_m, \sigma_m, q_0, \sigma_e, d_i, R_i$, and

| Table 2. Criteria for predictive diagnosis by CDR analysis |
|-----------------|-----------------|-----------------|
| **Not exceedingly low** | **Slight oscillation** | **High oscillation** |
| $\max\{D_2(Q_2)\} \geq L$ | Outlaw receptor pathway | Promiscuous receptor pathway | Hyper sensitivity |
| $\max\{D_2(Q_2)\} < L$ | Bypass pathway | No mechanism | No mechanism |

**NOTE:** The major mechanism of treatment resistance inherent in a given patient after a period of IAD is identified on the basis of $F_2$ (the amplitude of CR CDR oscillation), $\max\{D_2(Q_2)\}$ (the maximum CR CDR), and their relationships with three threshold values set as $L = 0.013$ day$^{-1}$, $T_0 = 0.0003$ day$^{-1}$, and $T_1 = 0.0013$ day$^{-1}$. See Simulations and diagnosis for criteria elucidation. We propose no mechanism for exceedingly low and oscillating CDRs.
δ_i = 1, 2. The remaining model parameters were held fixed across patients (see Table 1 for ranges and values).

Simulations and diagnosis
To identify the major mechanism of resistance for each patient, we establish criteria based on \( F_0 \), the total CDR oscillation amplitude defined in Equation H. Because the amplitude of CDR oscillation reflects the degree to which a population depends on androgens for survival, and because each mechanism varies in its degree of dependence on androgens for survival, we propose that there exist threshold CDR oscillation amplitudes that distinguish one mechanism from another. Specifically, we define two threshold values, \( T_0 \) and \( T_1 \). For \( 0 < F_1 < T_0 \), the CDR is said to be relatively constant and the population is, thus, relatively independent of androgens for survival. For \( F_1 = 0 \), which occurs when \( d_i = 0 \) or \( R_i = 0 \) (\( Q_{i,\text{max}}^0 \) and \( Q_{i,\text{max}}^1 \) are never equal), the CDR is constant and the population is completely independent of androgens for survival. For \( T_0 < F_1 < T_1 \), the CDR is said to slightly oscillate with respect to oscillation in androgen concentration and the population, thus, retains some dependence on androgens for survival. For \( T_1 < F_1 \), we say that there is relatively high oscillation in the CDR with respect to oscillation in androgen concentration and the population is, thus, completely dependent on androgens for survival. We also define a threshold \( L \), such that for \( \max[D_i(Q_i)] < L \), the CDR is said to be exceedingly low. An exceedingly low CDR would be characteristic of a constitutively active antiapoptotic pathway such that apoptosis is directly inhibited in the population, i.e., the bypass pathway.

As a novel approach for computational molecular diagnosis, our threshold values for \( T_0 \), \( T_1 \), and \( L \) are estimated based on existing hypotheses and data relevant to this work. Model parameters were constrained to biologically relevant ranges when applicable. When estimating these values, we considered consistency with patient-specific clinical observations and with the relative frequency of each mechanism reported in the literature. The threshold values were estimated to be \( L = 0.013 \text{ day}^{-1} \), \( T_0 = 0.0003 \text{ day}^{-1} \), and \( T_1 = 0.0013 \text{ day}^{-1} \). Mutations in the AR gene that confer hypersensitivity are the most frequent mutations found in CRPC and there is strong evidence that AR overexpression is the main mechanism of CRPC development (15). Therefore, these threshold values were estimated such that 4 of 7 patients would be diagnosed with hypersensitivity. Thus, \( T_1 \) was estimated to be slightly below the CDR oscillation amplitude value of patient 7, \( F_2 = 0.0014 \text{ day}^{-1} \). Because patient 4 was the only patient proposed to have early onset of CRPC and had an exceedingly low CDR relative to others, \( L \) was estimated to be slightly above \( \max[D_i(Q_4)] = 0.0110 \text{ day}^{-1} \), the maximum CDR of patient 4. \( T_0 \) was estimated to be slightly above the CDR oscillation amplitude value of patient 2,
Although a given patient may develop CRPC due to a combination of mechanisms, we assume that it is primarily due to one major mechanism. If more than one mechanism is inherent in the population, the one that is the least dependent on androgens for survival is the major mechanism. Because the hypersensitivity pathway maintains the strongest dependence on androgens, we propose that patients developing resistance primarily through this pathway should exhibit a high oscillation amplitude $F_2$ with a maximum CDR that is not exceedingly low; i.e., $T_1 < F_2$ and $\max(D_2(Q_2)) \geq L$. The promiscuous receptor pathway, which is less dependent on androgens than the hypersensitivity pathway, should exhibit a smaller oscillation amplitude $F_2$ while maintaining a maximum CDR that is not exceedingly low; i.e., $T_0 < F_2 \leq T_1$ and $\max(D_2(Q_2)) \geq L$. We propose that the outlaw receptor pathway is less dependent on androgens than the promiscuous
androgens for survival, consistent with the notion of early onset of CRPC. Furthermore, patient 4 was diagnosed with the most aggressive and least androgen-dependent pathway according to our criteria, which is also consistent with early onset of CRPC.

In future studies, it will be important to assess how much data are required for CDR analysis. In this study, diagnoses were based on the entire datasets from the clinical trial, which varied from 1.5 to 3.5 cycles per patient. At this stage of its development, we believe at least one full cycle of treatment is needed. This includes data from start until shortly after the second on-treatment has begun and PSA has regressed to physiologic range. Ideally, physicians will continually test patients’ levels and update their diagnosis profile with subsequent targeted treatment.

Although the threshold values \( L, T_0, \) and \( T_1 \) remain to be validated clinically, even once these values are empirically determined it is possible that they will still be subject to variation among datasets, and among patients. As with most models used for clinical prediction, it is likely to require repeated updating and validation with new datasets (37). Furthermore, we expect such updates not only to involve these thresholds, but also to include modifications to the model itself. We recognize this study as one that is preliminary but that establishes the principles of CDR analysis—a novel computational method for molecular diagnosis—on which others may build.

Although we demonstrated how CDR analysis works using CRPC development as an example, this methodology may be applied to other types of cancer. In particular, other steroid hormone–driven malignancies, such as estrogen receptor–positive (ER+) breast cancers, share many similarities in terms of their progression. For example, certain ER+ breast cancers can be treated intermittently with LHRH analogues to suppress serum estrogen levels in combination with antiestrogens that directly inhibit ER signaling (38, 39), which is similar to the combination of LHRH analogues and antiandrogens in the total androgen blockade used for prostate cancer IAD.

Personalized therapy on the basis of identifying and targeting specific mechanisms of treatment resistance developing in

### Results and Discussion

For each patient, we computed the amplitudes of CDR oscillation \( F_2 \) given in Equation H and the maximum CDRs for CDR analysis. We then diagnosed each patient using the outlined criteria (see Table 2). Figure 1 shows the PSA, cell quota, CDR, and proliferation-rate plots for patient 1. Figure 2 shows the PSA plots for patients 2 to 7. Figure 3 shows the CDR plots for patients 2 to 7. The proliferation-rate and cell-quota plots for patients 2 to 7 are found in the Supplementary Material, as are the MSE values of the fitted model solutions and PSA data. Table 3 contains the predictive diagnosis for each patient based on our criteria for CDR analysis. As expected, none of the patients have cell populations with exceedingly low and oscillating CDRs.

As expected, our results suggest that most CR populations retain at least some degree of dependence on androgens for survival. Patient 4 is the only patient whose PSA level never dropped below 4 ng/mL within the first 8 months of treatment (see Fig. 2). Akakura and colleagues (9) concluded that IAD is likely ineffective for patients whose PSA levels do not fall below this stable level within the first 8 months of treatment. They suggest that failure for PSA levels to normalize within this time period is a sign of early onset of CRPC (9). Our results show that patient 4 is the only patient that did not have a highly oscillating CS CDR, meaning that the CS population for patient 4 was not fully dependent on androgens for survival, consistent with the notion of early onset of CRPC. Patients whose CS CDR oscillations are inside the range of \( T_v \), or \( F_1 < T_1 \), may, thus, be developing early onset of CRPC.

Table 3. Predictive diagnosis for each of 7 patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>( F_2 (\text{day}^{-1}) )</th>
<th>( F_3 (\text{day}^{-1}) )</th>
<th>( \text{max}(D_2(Q_2)) \text{(day}^{-1}) )</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>0.0068 &gt; ( T_1 )</td>
<td>0.0002 &gt; ( T_1 )</td>
<td>0.0184 &gt; ( L )</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td>Patient 2</td>
<td>0.0128 &gt; ( T_1 )</td>
<td>0 &lt; 0.0001 &lt; ( T_0 )</td>
<td>0.0166 &gt; ( L )</td>
<td>Outlaw receptor</td>
</tr>
<tr>
<td>Patient 3</td>
<td>0.0049 &gt; ( T_1 )</td>
<td>0.0015 &gt; ( T_1 )</td>
<td>0.0150 &gt; ( L )</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td>Patient 4</td>
<td>( T_0 &lt; 0.0011 &lt; T_1 )</td>
<td>0 &lt; 0.0002 &lt; ( T_0 )</td>
<td>0.0110 &lt; ( L )</td>
<td>Bypass</td>
</tr>
<tr>
<td>Patient 5</td>
<td>0.0083 &gt; ( T_1 )</td>
<td>0.0035 &gt; ( T_1 )</td>
<td>0.0193 &gt; ( L )</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td>Patient 6</td>
<td>0.0036 &gt; ( T_1 )</td>
<td>( T_0 &lt; 0.0008 &lt; T_1 )</td>
<td>0.0169 &gt; ( L )</td>
<td>Promiscuous receptor</td>
</tr>
<tr>
<td>Patient 7</td>
<td>0.0074 &gt; ( T_1 )</td>
<td>0.0014 &gt; ( T_1 )</td>
<td>0.0194 &gt; ( L )</td>
<td>Hypersensitivity</td>
</tr>
</tbody>
</table>

NOTE: These diagnoses were carried out using criteria for predictive diagnosis by CDR analysis outlined in Table 2 on the basis of \( F_2 \) (the amplitude of CR CDR oscillation), \( \text{max}(D_2(Q_2)) \) (the maximum CR CDR), and threshold values \( L = 0.013\text{day}^{-1}, T_0 = 0.0003\text{day}^{-1}, \) and \( T_1 = 0.0013\text{day}^{-1}. \)
individual patients is likely one of the most promising methods of future cancer therapy. CDR analysis is a method for identifying the mechanism, which physicians can then conceivably target, thus reestablishing treatment sensitivity in these patients. Sequential identification and targeting of resistance mechanisms may potentially control or eradicate cancers.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: J.D. Morken, A. Packer, R.A. Everett, Y. Kuang
Development of methodology: J.D. Morken, A. Packer, R.A. Everett, Y. Kuang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Kuang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.D. Morken, A. Packer, R.A. Everett, J.D. Nagy, Y. Kuang
Writing, review, and/or revision of the manuscript: J.D. Morken, A. Packer, R.A. Everett, J.D. Nagy, Y. Kuang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Packer
Study supervision: J.D. Nagy

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 5, 2013; revised April 9, 2014; accepted April 24, 2014; published OnlineFirst May 22, 2014.

Figure 3. A–F, CDR plots (day⁻¹) for patients 2 to 7, respectively. The x-axis is time in days.
References

Mechanisms of Resistance to Intermittent Androgen Deprivation in Patients with Prostate Cancer Identified by a Novel Computational Method

Jason D. Morken, Aaron Packer, Rebecca A. Everett, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-3162

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/06/03/0008-5472.CAN-13-3162.DC1

Cited articles
This article cites 40 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/14/3673.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/74/14/3673.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.